SomaLogic, a Boulder, CO-based provider of a platform that delivers actionable health-management insights for individuals to optimize their personal health and wellness, closed a $200m funding round.
The round was anchored by iCarbonX with substantial investments from Nan Fung Life Sciences and Madryn Asset Management.
The company intends to use the funds to continue to grow globally.
Led by Al Reynolds, CEO, SomaLogic measures thousands of human proteins rather than genes, and turns those measurements into insights that enable people to meaningfully manage their individual health and wellness. The company’s “SOMAscan®” technology, which currently measures 5,000 proteins in a single sample, has analyzed over 150,000 samples across more than 50 diseases or conditions, with plans for an additional 1 million more samples by the end of 2020.